What’s new in non-alcoholic fatty liver disease?

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with an estimated prevalence of 25% in the Western World. NAFLD is a broad spectrum of disease states and while most people with NAFLD do not have progressive disease, 10-20% of patients develop histologic...

Full description

Saved in:
Bibliographic Details
Published inFrontline Gastroenterology Vol. 13; no. e1; pp. e102 - e108
Main Authors Spiers, Jessica, Brindley, James Hallimond, Li, Wenhao, Alazawi, William
Format Journal Article Book Review
LanguageEnglish
Published England BMJ Publishing Group Ltd 01.08.2022
BMJ Publishing Group LTD
BMJ Publishing Group
SeriesReview
Subjects
Biomarkers
Biopsy
Dentistry
Diabetes
FATTY LIVER
FIBROSIS
Gastroenterology
Genes
Genomes
Health risk assessment
Licenses
Liver
Liver cirrhosis
Liver diseases
Metabolism
Mortality
Primary care
Risk factors
United Kingdom > UK
FIBROSIS
FATTY LIVER
Online AccessGet full text

Cover

More Information
Summary:Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with an estimated prevalence of 25% in the Western World. NAFLD is a broad spectrum of disease states and while most people with NAFLD do not have progressive disease, 10-20% of patients develop histological features of inflammation (non-alcoholic steatohepatitis), fibrosis, cirrhosis and its complications. Despite this large disease burden of significant clinical impact, most people living with NAFLD are undiagnosed, disease course prediction is imprecise and there are no treatments licensed for this condition. In this review, we discuss some of the recent developments in NAFLD, focusing on disease definition and diagnosis, risk stratification and treatments.
Bibliography:Review
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-4137
2041-4145
DOI:10.1136/flgastro-2022-102122